ACE-031 Benefits: What Studies Report

What the published ACE-031 literature covers

ACE-031 was developed as a soluble activin type IIB receptor (ActRIIB) fusion protein, an approach described in a nonhuman primate report that characterised it as a soluble activin type IIB receptor and examined muscle mass and strength in the common marmoset (PMID 41686840). The clinical record is small. A single ascending-dose study in healthy postmenopausal women reported changes in lean body mass and muscle volume (PMID 23169607), and a randomised, placebo-controlled trial in ambulatory boys with Duchenne muscular dystrophy (DMD) reported body-composition changes but was discontinued before completion (PMID 27462804). This page organises what those publications measured and the direction of effect they described. It does not present any outcome as established, and it is not a protocol.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or treatment decision. ACE-031 is not an approved medicine in the United States or elsewhere; material sold under that name is handled as research-use-only chemical rather than as a therapeutic product.

How to read "benefits" for an investigational molecule

In the ACE-031 literature, an outcome is only as strong as the design that produced it. A single-dose study in healthy volunteers can describe short-term biomarker and imaging changes but cannot speak to function or durability (PMID 23169607). A randomised trial that was stopped early for safety reasons produces incomplete efficacy data by definition (PMID 27462804). Animal work describes what happened in that species under those conditions, as in the marmoset experiments (PMID 41256654). Each domain below is labelled with study type and population so the reader can see which of these applies.

Outcome domain: lean body mass and body composition

Healthy adults — single ascending-dose study

In the single ascending-dose study of ACE-031 in healthy volunteers, researchers administered single subcutaneous doses across escalating dose levels to healthy postmenopausal women and reported increases in lean body mass relative to baseline, together with changes in total body fat mass (PMID 23169607). The study was designed primarily around safety, tolerability and pharmacodynamic signals rather than around any functional endpoint, and the direction of the body-composition change was the principal pharmacodynamic observation the researchers described (PMID 23169607).

Duchenne muscular dystrophy — randomised, placebo-controlled trial

In the randomised, placebo-controlled trial of ACE-031 in ambulatory boys with DMD, the study reported increases in lean body mass and decreases in fat mass in treated participants compared with placebo, measured by dual-energy X-ray absorptiometry (PMID 27462804). Because dosing was halted before the planned treatment period ended, the researchers described these observations as drawn from a truncated dataset (PMID 27462804).

Outcome domain: muscle volume and muscle mass

Thigh muscle volume measured by imaging was among the pharmacodynamic endpoints in the healthy-volunteer single ascending-dose study, where researchers reported increases following a single subcutaneous administration (PMID 23169607). In nonhuman primates, the marmoset work reported increased muscle mass after ACE-031 administration (PMID 41686840); the same experiments were first released as a preprint describing increases in muscle mass and strength in the common marmoset (PMID 41256654). These are animal data and the species, dosing conditions and measurement methods differ from anything tested in people.

Outcome domain: muscle strength and physical function

This is the domain where searches for "ACE-031 benefits" most often outrun the evidence. The only strength finding in the verified literature comes from nonhuman primates: the marmoset report described increases in muscle strength alongside increases in muscle mass (PMID 41686840, preprint version PMID 41256654). In humans, the DMD trial examined functional endpoints including the 6-minute walk distance, and the researchers reported that the trial was discontinued early so that the planned efficacy assessment could not be completed as designed (PMID 27462804). The single-dose healthy-volunteer study did not set out to measure strength or performance (PMID 23169607).

Outcome domain: bone biomarkers

The healthy-volunteer study also tracked markers of bone metabolism, and researchers reported changes in bone formation and bone resorption biomarkers after single subcutaneous dosing in healthy postmenopausal women (PMID 23169607). Biomarker movement is not the same as a change in fracture risk, bone density outcomes or any clinical endpoint, and the study did not report such endpoints (PMID 23169607).

Mechanistic and review context

Two 2011 Japanese-language review articles placed myostatin-pathway blockade in the context of muscle-wasting conditions and myopathies, discussing the rationale for interfering with myostatin signalling (PMID 22277518; PMID 22068480). Reviews of this kind summarise a research direction rather than generate new outcome data, and neither constitutes evidence that any particular ACE-031 outcome occurs in a given population (PMID 22068480).

Outcomes commonly associated with ACE-031 where published evidence is thin or absent

Several outcomes attached to ACE-031 in general discussion are not supported by the verified publications. The healthy-volunteer study and the DMD trial together represent the human record, and neither reported athletic performance, body-recomposition over months, injury recovery, or any ageing-related outcome (PMID 23169607; PMID 27462804).

• Strength gains in healthy adults: not an endpoint of the single ascending-dose study, which was built around safety, tolerability and pharmacodynamics (PMID 23169607).
• Long-term muscle maintenance: the DMD trial, the longest-running human exposure in this set, was discontinued early (PMID 27462804).
• Fat loss as a therapeutic goal: fat-mass change was recorded as a body-composition observation in the DMD trial, not as a weight-management outcome (PMID 27462804).
• Bone density or fracture outcomes: only biomarkers were reported in healthy postmenopausal women, not clinical bone endpoints (PMID 23169607).
• Use in sarcopenia, cachexia or other wasting states: discussed conceptually in review form (PMID 22277518) without ACE-031 outcome trials in those populations in this citation set.

Adverse Events in ACE-031 Studies: What Studies Report

Safety findings are the reason the clinical programme is discussed in the past tense. In the single ascending-dose study in healthy postmenopausal women, researchers reported adverse events including dilated blood vessels in the skin (telangiectasias) and bleeding events such as nosebleeds and gum bleeding (PMID 23169607). In the randomised, placebo-controlled DMD trial, the study reported that dosing was stopped early because of epistaxis and telangiectasia observed in treated participants (PMID 27462804). Any reading of the body-composition findings has to be set against those reports from the same publications (PMID 27462804).

Evidence map

How strong is the overall evidence?

Judged by the usual criteria — number of participants, replication, length of follow-up and completeness of trials — the ACE-031 evidence base is early and interrupted. The largest controlled human dataset came from a trial that was stopped before its planned endpoint assessment (PMID 27462804), the healthy-volunteer data came from single doses rather than repeated administration (PMID 23169607), and the strength findings sit in a nonhuman primate model (PMID 41686840). Consistent direction of effect on muscle mass across those settings is an observation about measurement, not a demonstration that a clinical benefit follows (PMID 41256654).

Readers comparing sources should also note that the 2026 journal article and the 2025 preprint describe the same marmoset experiments at different stages of peer review (PMID 41686840; PMID 41256654), so they should not be counted as two independent replications.

References

• A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers (Muscle & Nerve, 2013)
• Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial (Muscle & Nerve, 2017)
• ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus) (PLoS One, 2026)
• ACE-031, a Soluble Activin Type IIB Receptor, Increases Muscle Mass and Strength in the Common Marmoset (Callithrix jacchus) (bioRxiv, 2025)
• [Anti-myostatin antibody therapy for myopathies] (Rinsho Shinkeigaku, 2011)
• [Myostatin blockade therapy for muscular atrophy] (Brain and Nerve, 2011)